Bioxodes SA
Description
Bioxodes, a clinical-stage biopharmaceutical company, focuses on developing effective treatments for thrombo-inflammatory related conditions. Its lead candidate, BIOX-101 (Ir-CPI), is currently in Phase 2a clinical trial for hemorrhagic stroke, a devastating disease for which there currently is no available treatment. The company has enrolled its first 8 patients and expects to publish interim results from the first 16 patients in the second half of 2024. The active ingredient in BIOX-101 is derived from the saliva of the tick (Ixodes ricinus). A first-in-class drug candidate combining antithrombotic and anti-inflammatory properties, BIOX-101 is an innovative antithrombotic aiming to prevent dangerous blood clotting without causing further bleeding, inhibiting both clotting factors and neutrophils. BIOX-101 shows promise for conditions in which patients face risks of bleeding, clotting, and neuroinflammation contributing significantly to neurological decline, mortality or poor functional outcomes.
